Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 6Breast 3Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 2Thymus Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Neoplasm Metastasis 1Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Digestive System Neoplasms 1Carcinosarcoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 50Cyclophosphamide 25Carboplatin 25Gemcitabine 20Cisplatin 19fludarabine 18Nivolumab 17Paclitaxel 16Bevacizumab 15Specimen Handling 14Fluorouracil 11Magnetic Resonance Spectroscopy 10aldesleukin 9Oxaliplatin 9Irinotecan 9Docetaxel 9Biopsy 9olaparib 8Trastuzumab 8durvalumab 7atezolizumab 7Hyperthermic Intraperitoneal Chemotherapy 7Albumin-Bound Paclitaxel 7Taxes 6Leucovorin 6Ipilimumab 6Interleukin-2 6Cetuximab 6Capecitabine 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × ribociclib × Gastrointestinal × Clear all
NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡